Precision Pathology will develop the CyPath Lung test for early-stage detection of lung cancer as an LDT for commercial sale by the first-quarter of 2019.
Martin Edelman will investigate whether cancer associated macrophage-like cells can determine whether small or indeterminate lung nodules are cancerous or benign.
The firm reported that it has signed contracts for a total of 430 instruments, while commercial placements grew to 118 across the globe.
The system is designed to provide a quantitative determination of red blood cells and total nucleated cells in CSF.
The company will supply the Chinese laboratory with its ClearCell FX1 system and help train and assist its new partner in developing cancer tests.
The firm has begun validating its porphyrin molecule marker test for use with flow cytometry at four sites and anticipates adding four, or more, to complete the validation.
The financing will support business expansion, continued technology development, and expenses related to a planned listing at the end of the year.
The deal begins commercialization of Emosis' first test for heparin-induced thrombocytopenia in at least 36 countries that recognize CE marking.
The financing will go toward further development of Klaris' phenotypic single-cell technology that can rapidly identify pathogens and determine their response to antibiotics.
Amid reporting a loss of about $2.0 million for the quarter, Celcuity also said that it had completed the development of its second test, for breast cancer, based on the CELx platform.